hyperimmune globulin
/ Intas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 27, 2020
Intas gets DCGI nod for clinical trials of hyperimmune globulin for COVID-19 treatment
(ExpressPharma)
- "Intas Pharma has received permission from the Drug Controller General of India (DCGI), to conduct clinical trial of its COVID-19 specific hyperimmune globulin as treatment for patients suffering from moderate to severe COVID-19 infection....This will be a Corporate Social Responsibility (CSR) initiative from Intas in collaboration with all Indian blood banks, that will help to procure convalescent plasma..."
New trial • Infectious Disease • Novel Coronavirus Disease
1 to 1
Of
1
Go to page
1